VELCADE,Rituximab,Cyclophosphamide and Decadron (VRCD)
Phase II Study Investigating the Efficacy of VELCADE®, Rituximab, Cyclophosphamide and Decadron (VRCD Regimen) in Front-line Therapy of Patients With Low-grade Non-Hodgkin's Lymphoma
Sponsor: Millennium Pharmaceuticals, Inc.
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Millennium Pharmaceuticals, Inc.
- Relapsed or Refractory Systemic Light Chain Amyloidosis · Phase PHASE3 · Jul 2022
- Lymphoma, Non-Hodgkin · Phase PHASE1 · Jul 2020
- Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies · Phase PHASE1 · Feb 2020
- Acute Myeloid Leukemia (AML) · Phase PHASE2 · Jul 2019
- Mantle Cell Lymphoma · Phase PHASE1 · Apr 2019
More terminations from Millennium Pharmaceuticals, Inc.
A PHASE2 clinical study on Lymphoma, B-Cell and Lymphoma, Non-Hodgkin, this trial is terminated or withdrawn. The trial is conducted by Millennium Pharmaceuticals, Inc. and has accumulated 6 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Oct 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Millennium Pharmaceuticals, Inc.
- Oncology Specialists, S.C.
For direct contact, visit the study record on ClinicalTrials.gov .